



06/12/06

1645#

JPN

Atty. Docket No.: 227045/1020

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Weinstock et al.
Serial No.: 09/362,598
Filed: July 28, 1999
Entitled: Use of Parasitic Biological Agents
for Prevention and Control of
Autoimmune Diseases

Examiner: Zeman, R.

Group Art Unit: 1645


Conf. No.: 7062

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EV755068179US** on this date **June 8, 2006**, postage prepaid, in an envelope addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Katie Manzione

Name of Person Mailing Paper


Signature of Person Mailing Paper

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing the above-identified patent application, please find the following documents:

1. Amendment and Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Copy of Notice to Comply;
3. Paper copy of Sequence Listing;
4. Computer readable copy of the Sequence Listing;
5. Three months Extension of Time for Filing the Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures; and
6. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 227045/1020. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: June 8, 2006
Name: Matthew Beaudet

Registration No.: 50,649

Customer No.: 29933

Edwards Angell Palmer & Dodge LLP

P.O. Box 55874

Boston, MA 02205 Tel: 617-239-0100



Atty. Docket No.: 227045/1020

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Weinstock et al.
Serial No.: 09/362,598
Filed: July 28, 1999
Entitled: Use of Parasitic Biological Agents
for Prevention and Control of
Autoimmune Diseases

Examiner: Zeman, R.

Group Art Unit: 1645

Conf. No.: 7062

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the paper (and any paper or fee referred to as being enclosed) is being deposited with the United States Postal Service using Express Mail to Addressee Service, under 37 C.F.R. Section 1.10, **Express Mail Label No. EV755068179US** on this date **June 8, 2006**, postage prepaid, in an envelope addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Katie Manzione

Name of Person Mailing Paper

Katie Manzione

Signature of Person Mailing Paper

Mail Stop Sequence

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**


Sir:

A corrected sequence listing is submitted in response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures mailed by the PTO on February 8, 2006 in which the sequence listing has been updated to include reference to the relevant priority applications and respective filing dates.

Applicants, in compliance with 37 C.F.R. 1.821(f), hereby state that the information recorded in computer readable form submitted herewith is identical to the written sequence listing. Applicants, in compliance with 37 C.F.R. 1.821(g), further state that no new matter is added.

Date: June 8, 2006

Respectfully submitted,


Name: Matthew Beaudet

Registration No.: 50,649


Customer No.: 29933

Edwards Angell Palmer & Dodge LLP

P.O. Box 55874

Boston, MA 02205

Tel: 617-239-0100

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

•Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. . 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a ☐Sequence Listing☐ as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the Sequence Listing in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the Sequence Listing in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up Raw Sequence Listing.
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the Sequence Listing is not the same as the computer readable from of the ☐Sequence Listing☐ as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: the sequence listing of record does not properly list the prior application numbers and their respective filing dates. See MPEP 2424.02..

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the Sequence Listing..
- ☒ An initial or substitute paper copy of the ☐Sequence Listing, as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY